Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Palliative Care × Dermatologic × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Tumor-Agnostic 1 Thoracic 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Interventions

pembrolizumab 34 Nivolumab 33 Specimen Handling 20 Ipilimumab 19 Magnetic Resonance Spectroscopy 17 Cyclophosphamide 13 Biopsy 13 trametinib 11 CTLA-4 Antigen 8 fludarabine 7 cemiplimab 6 fludarabine phosphate 5 encorafenib 5 dabrafenib 5 binimetinib 5 relatlimab 4 Radiosurgery 4 Introns 4 Interleukin-2 4 Interferon alpha-2 4 tebentafusp 3 naporafenib 3 cabozantinib 3 atezolizumab 3 aldesleukin 3 Vemurafenib 3 Standard of Care 3 Paclitaxel 3 Opdualag 3 Immunoglobulin G 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02645149 2026-02-27

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡